The Anti-fibrotic Effects of Heat-Killed Akkermansia muciniphila MucT on Liver Fibrosis Markers and Activation of Hepatic Stellate Cells.
Akkermansia muciniphila
Gene expression
Heat-killed bacteria
Hepatic stellate cell
LX-2 cells
Liver fibrosis
Journal
Probiotics and antimicrobial proteins
ISSN: 1867-1314
Titre abrégé: Probiotics Antimicrob Proteins
Pays: United States
ID NLM: 101484100
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
accepted:
09
12
2020
pubmed:
13
1
2021
medline:
30
12
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
Hepatic stellate cell (HSC) activation is a key phenomenon in development of liver fibrosis. Recently, Akkermansia muciniphila has been introduced as a next-generation microbe residing in the mucosal layer of the human gut. Due to the probable risks associated with the use of live probiotics, the tendency to use heat-killed bacteria has been raised. Herein, we investigated the potential anti-fibrotic effects of heat-killed A. muciniphila MucT on activation of HSCs. The human LX-2 cells were stimulated by various concentrations of LPS to evaluate the optimal concentration for HSC activation. Cell viability of LX-2 cells treated with LPS and heat-killed A. muciniphila MucT was measured by MTT assay. Scanning electron microscopy was used to analyze the morphology of heat-killed bacteria. Quiescent and LPS-stimulated LX-2 cells were coinfected with heat-killed A. muciniphila MucT. The gene expression of α-SMA, TIMP, Col1, TGF-β, TLR4, and PPARγ was analyzed using quantitative real-time PCR. Our results showed that LPS treatment led to a significant increase in fibrosis markers in a concentration-independent manner (P < 0.0001), and significantly downregulated the expression of PPARγ (P < 0.0001). The heat-killed A. muciniphila MucT could significantly modulate the expression of fibrosis markers particularly in MOI 10 (P < 0.0001), and reversed the HSC activation in LPS-stimulated LX-2 cells. In conclusion, we demonstrated that heat-killed A. muciniphila MucT was safe and capable to ameliorate LPS-induced HSC activation through modulation of fibrosis markers. Further in vivo studies are required to validate the anti-fibrotic properties of heat-killed A. muciniphila MucT.
Identifiants
pubmed: 33433897
doi: 10.1007/s12602-020-09733-9
pii: 10.1007/s12602-020-09733-9
doi:
Substances chimiques
Lipopolysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
776-787Références
Ottman N, Geerlings SY, Aalvink S, de Vos WM, Belzer C (2017) Action and function of Akkermansia muciniphila in microbiome ecology, health and disease. Best Pract Res Clin Gastroenterol 31:637–642. https://doi.org/10.1016/j.bpg.2017.10.001
doi: 10.1016/j.bpg.2017.10.001
pubmed: 29566906
Ottman N, Davids M, Suarez-Diez M, Boeren S, Schaap PJ, Martins Dos Santos VAP, Smidt H, Belzer C et al (2017) Genome-scale model and omics analysis of metabolic capacities of Akkermansia muciniphila reveal a preferential mucin-degrading lifestyle. Appl Environ Microbiol 83:e01014-e1017. https://doi.org/10.1128/aem
doi: 10.1128/aem
pubmed: 28687644
pmcid: 5583483
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G et al (2019) Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 25:1096–1103. https://doi.org/10.1038/s41591-019-0495-2
doi: 10.1038/s41591-019-0495-2
pubmed: 31263284
pmcid: 6699990
Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD et al (2016) Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65:426–436. https://doi.org/10.1136/gutjnl-2014-308778
doi: 10.1136/gutjnl-2014-308778
pubmed: 26100928
Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y et al (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 8:e71108. https://doi.org/10.1371/journal.pone.0071108
doi: 10.1371/journal.pone.0071108
pubmed: 24013136
pmcid: 3754967
Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA et al (2010) Mucolytic bacteria with increased prevalence in IBD mucosa augmentin vitroutilization of mucin by other bacteria. Am J Gastroenterol 105:2420–2428. https://doi.org/10.1038/ajg.2010.281
doi: 10.1038/ajg.2010.281
pubmed: 20648002
Swidsinski A, Dörffel Y, Loening-Baucke V, Theissig F, Rückert JC, Ismail M, Rau WA et al (2011) Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum. Gut 60:34–40. https://doi.org/10.1136/gut.2009.191320
doi: 10.1136/gut.2009.191320
pubmed: 19926616
Derrien M, Van Baarlen P, Hooiveld G, Norin E, Muller M, de Vos WM (2011) Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol 2:166–180. https://doi.org/10.3389/fmicb.2011.00166
doi: 10.3389/fmicb.2011.00166
pubmed: 21904534
pmcid: 3153965
Del Chierico F, Nobili V, Vernocchi P, Russo A, Stefanis CD, Gnani D, Furlanello C et al (2017) Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65:451–464. https://doi.org/10.1002/hep.28572
doi: 10.1002/hep.28572
pubmed: 27028797
Özkul C, Yalınay M, Karakan T, Yılmaz G (2017) Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 28:361–369. https://doi.org/10.5152/tjg.2017.17033
doi: 10.5152/tjg.2017.17033
pubmed: 28705785
Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, Ward DV et al (2018) Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 67:891–901. https://doi.org/10.1136/gutjnl-2016-313432
doi: 10.1136/gutjnl-2016-313432
pubmed: 28550049
Povero D, Pinatel EM, Leszczynska A, Goyal NP, Nishio T, Kim J, Kneiber D et al (2019) Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. JCI Insight 5:e125652. https://doi.org/10.1172/jci.insight.125652
doi: 10.1172/jci.insight.125652
Weiskirchen R, Weiskirchen S, Tacke F (2019) Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications. Mol Aspects Med 65:2–15. https://doi.org/10.1016/j.mam.2018.06.003
doi: 10.1016/j.mam.2018.06.003
pubmed: 29958900
Moreira RK (2007) Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 131:1728–1734. https://doi.org/10.1043/1543-2165(2007)131[1728:HSCALF]2.0.CO;2
doi: 10.1043/1543-2165(2007)131[1728:HSCALF]2.0.CO;2
pubmed: 17979495
Shang L, Hosseini M, Liu X, Kisseleva T, Brenner DA (2018) Human hepatic stellate cell isolation and characterization. J Gastroenterol 53:6–17. https://doi.org/10.1007/s00535-017-1404-4
doi: 10.1007/s00535-017-1404-4
pubmed: 29094206
Deshpande G, Athalye-Jape G, Patole S (2018) Para-probiotics for preterm neonates-the next frontier. Nutrients 10:871. https://doi.org/10.3390/nu10070871
doi: 10.3390/nu10070871
pmcid: 6073938
Adams CA (2010) The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev 23:37–46. https://doi.org/10.1017/S0954422410000090
doi: 10.1017/S0954422410000090
pubmed: 20403231
Taverniti V, Guglielmetti S (2011) The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr 6:261–274. https://doi.org/10.1007/s12263-011-0218-x
doi: 10.1007/s12263-011-0218-x
pubmed: 21499799
pmcid: 3145061
Piqué N, Berlanga M, Miñana-Galbis D (2019) Health benefits of heat-killed (tyndallized) probiotics: an overview. Int J Mol Sci 20:2534–2564. https://doi.org/10.3390/ijms20102534
doi: 10.3390/ijms20102534
pmcid: 6566317
Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. PNAS 110:9066–9071. https://doi.org/10.1073/pnas.1219451110
doi: 10.1073/pnas.1219451110
pubmed: 23671105
Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J et al (2017) A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23:107–113. https://doi.org/10.1038/nm.4236
doi: 10.1038/nm.4236
pubmed: 27892954
Derrien M, Vaughan EE, Plugge CM, de Vos WM (2004) Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol 54:1469–1476. https://doi.org/10.1099/ijs.0.02873-0
doi: 10.1099/ijs.0.02873-0
Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T et al (2019) Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 4:492–503. https://doi.org/10.1038/s41564-018-0333-1
doi: 10.1038/s41564-018-0333-1
pubmed: 30643240
Sun Q, Li F, Li H, Chen R-H, Gu Y-Z, Chen Y, Liang H-S et al (2015) Amniotic fluid stem cells provide considerable advantages in epidermal regeneration: B7H4 creates a moderate inflammation microenvironment to promote wound repair. Sci Rep 5:11560–11575. https://doi.org/10.1038/srep11560
doi: 10.1038/srep11560
pubmed: 26101181
pmcid: 4477371
Zhao L, Ma R, Zhang L, Yuan X, Wu J, He L, Liu G et al (2019) Inhibition of HIF-1a-mediated TLR4 activation decreases apoptosis and promotes angiogenesis of placental microvascular endothelial cells during severe pre-eclampsia pathogenesis. Placenta 83:8–16. https://doi.org/10.1016/j.placenta.2019.06.375
doi: 10.1016/j.placenta.2019.06.375
pubmed: 31477211
Parola M, Pinzani M (2019) Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 65:37–55. https://doi.org/10.1016/j.mam.2018.09.002
doi: 10.1016/j.mam.2018.09.002
pubmed: 30213667
Higashi T, Friedman SL, Hoshida Y (2017) Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 121:27–42. https://doi.org/10.1016/j.addr.2017.05.007
doi: 10.1016/j.addr.2017.05.007
pubmed: 28506744
pmcid: 5682243
Kitano M, Bloomston PM (2016) Hepatic stellate cells and microRNAs in pathogenesis of liver fibrosis. J Clin Med 5:38–57. https://doi.org/10.3390/jcm5030038
doi: 10.3390/jcm5030038
pmcid: 4810109
Albillos A, de Gottardi A, Rescigno M (2020) The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 72:558–577. https://doi.org/10.1016/j.jhep.2019.10.003
doi: 10.1016/j.jhep.2019.10.003
pubmed: 31622696
Zhou R, Fan X, Schnabl B (2019) Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 209:22–38. https://doi.org/10.1016/j.jhep.2019.10.003
doi: 10.1016/j.jhep.2019.10.003
pubmed: 30853445
Safari Z, Gérard P (2019) The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 76:1541–1558. https://doi.org/10.1007/s00018-019-03011-w
doi: 10.1007/s00018-019-03011-w
pubmed: 30683985
Hollister EB, Gao C, Versalovic J (2014) Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 146:1449–1458. https://doi.org/10.1053/j.gastro.2014.01.052
doi: 10.1053/j.gastro.2014.01.052
pubmed: 24486050
pmcid: 4181834
Cani PD, de Vos WM (2017) Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 8:1765–1773. https://doi.org/10.3389/fmicb.2017.01765
doi: 10.3389/fmicb.2017.01765
pubmed: 29018410
pmcid: 5614963
Thingholm LB, Rühlemann MC, Koch M, Fuqua B, Laucke G, Boehm R, Bang C et al (2019) Obese individuals with and without type 2 diabetes show different gut microbial functional capacity and composition. Cell Host Microbe 26:252-264.e210. https://doi.org/10.5005/jp-journals-10018-1233
doi: 10.5005/jp-journals-10018-1233
pubmed: 31399369
pmcid: 7720933
Nistal E, Saenz de Miera LE, Ballesteros Pomar M, Sánchez Campos S, García Mediavilla MV, Álvarez Cuenllas B, Linares P et al (2019) An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. Rev Esp Enferm Dig 111:275–282. https://doi.org/10.17235/reed.2019.6068/2018
doi: 10.17235/reed.2019.6068/2018
pubmed: 30810328
Addolorato G, Ponziani FR, Dionisi T, Mosoni C, Vassallo GA, Sestito L, Petito V et al (2020) Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. Liver Int 40:878–888. https://doi.org/10.1111/liv.14383
doi: 10.1111/liv.14383
pubmed: 31951082
Lavekar AS, Raje DV, Manohar T, Lavekar AA (2017) Role of probiotics in the treatment of nonalcoholic fatty liver disease: a meta-analysis. Euroasian J Hepatogastroenterol 7:130–137. https://doi.org/10.5005/jp-journals-10018-1233
doi: 10.5005/jp-journals-10018-1233
Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, Shao T et al (2019) Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. Hepatology 7:2050–2066. https://doi.org/10.1002/hep.30975
doi: 10.1002/hep.30975
Ahn SB, Jun DW, Kang B-K, Lim JH, Lim S, Chung M-J (2019) Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep 9:5688–5697. https://doi.org/10.1038/s41598-019-42059-3
doi: 10.1038/s41598-019-42059-3
pubmed: 30952918
pmcid: 6450966
O’neill LA, Golenbock D, Bowie AG, (2013) The history of toll-like receptors-redefining innate immunity. Nat Rev Immunol 13:453–460. https://doi.org/10.1038/nri3446
doi: 10.1038/nri3446
Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF (2007) TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 13:1324–1332. https://doi.org/10.1038/nm1663
doi: 10.1038/nm1663
pubmed: 17952090
Kim SY, Seki E (2020) Toll‐like receptors in liver disease. In: The liver: biology and pathobiology (ed), 6th edn. John Wiley & Sons Ltd, pp 737–746. https://doi.org/10.1002/9781119436812.ch57
Ouyang Y, Guo J, Lin C, Lin J, Cao Y, Zhang Y, Wu Y et al (2016) Transcriptomic analysis of the effects of toll-like receptor 4 and its ligands on the gene expression network of hepatic stellate cells. Fibrogenesis Tissue Repair 9:2. https://doi.org/10.1186/s13069-016-0039-z
doi: 10.1186/s13069-016-0039-z
pubmed: 26900402
pmcid: 4759739
Yuan Y, Han Q, Li S, Tian Z, Zhang J (2017) Wnt2b attenuates HSCs activation and liver fibrosis through negative regulating TLR4 signaling. Sci Rep 7:3952. https://doi.org/10.1038/s41598-017-04374-5
doi: 10.1038/s41598-017-04374-5
pubmed: 28638086
pmcid: 5479809
Ottman N, Reunanen J, Meijerink M, Pietilä TE, Kainulainen V, Klievink J, Huuskonen L et al (2017) Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS ONE 12:e0173004-e173022. https://doi.org/10.1371/journal.pone.0173004
doi: 10.1371/journal.pone.0173004
pubmed: 28249045
pmcid: 5332112
Ashrafian F, Shahryari A, Behrouzi A, Moradi HR, Keshavarz Azizi Raftar S, Lari A, Hadifar S (2019) Akkermansia muciniphila-derived extracellular vesicles as a mucosal delivery vector for amelioration of obesity in mice. Front Microbiol 10:2155–2171. https://doi.org/10.3389/fmicb.2019.02155
doi: 10.3389/fmicb.2019.02155
pubmed: 31632356
pmcid: 6779730
Hänninen A, Toivonen R, Pöysti S, Belzer C, Plovier H, Ouwerkerk JP, Emani R (2018) Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 67:1445–1453. https://doi.org/10.1136/gutjnl-2017-314508
doi: 10.1136/gutjnl-2017-314508
pubmed: 29269438
Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397–411. https://doi.org/10.1038/nrgastro.2017.38
doi: 10.1038/nrgastro.2017.38
pubmed: 28487545
Kesar V, Odin JA (2014) Toll-like receptors and liver disease. Liver Int 34:184–196. https://doi.org/10.1111/liv.12315
doi: 10.1111/liv.12315
pubmed: 24118797
Park YJ, Kim DM, Jeong MH, Yu JS, So HM, Bang IJ, Kim HR et al (2020) (-)-Catechin-7-O-β-d-apiofuranoside inhibits hepatic stellate cell activation by suppressing the stat3 signaling pathway. Cells 9:30–47. https://doi.org/10.3390/cells9010030
doi: 10.3390/cells9010030
Zhang C-Y, Yuan W-G, He P, Lei J-H, Wang C-X (2016) Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 22:10512–10522. https://doi.org/10.3748/wjg.v22.i48.10512
doi: 10.3748/wjg.v22.i48.10512
pubmed: 28082803
pmcid: 5192262
Jantararussamee C, Rodniem S, Taweechotipatr M, Showpittapornchai U, Pradidarcheep W (2020) Hepatoprotective effect of probiotic lactic acid bacteria on thioacetamide-induced liver fibrosis in rats. Probiotics Antimicrob Proteins. https://doi.org/10.1007/s12602-020-09663-6
doi: 10.1007/s12602-020-09663-6
Wu W, Lv L, Shi D, Ye J, Fang D, Guo F, Li Y et al (2017) Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front Microbiol 8:1804–1817. https://doi.org/10.3389/fmicb.2017.01804
doi: 10.3389/fmicb.2017.01804
pubmed: 29033903
pmcid: 5626943
Tanaka N, Aoyama T, Kimura S, Gonzalez FJ (2017) Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther 179:142–157. https://doi.org/10.1016/j.pharmthera.2017.05.011
doi: 10.1016/j.pharmthera.2017.05.011
pubmed: 28546081
pmcid: 6659998
Rudraiah S, Zhang X, Wang L (2016) Nuclear receptors as therapeutic targets in liver disease: are we there yet? Annu Rev Pharmacol Toxicol 56:605–626. https://doi.org/10.1146/annurev-pharmtox-010715-103209
doi: 10.1146/annurev-pharmtox-010715-103209
pubmed: 26738480
pmcid: 4919666
Choi JH, Kim SM, Lee GH, Jin SW, Lee HS, Chung YC, Jeong HG (2019) Platyconic acid a, platycodi radix-derived saponin, suppresses TGF-β1-induced activation of hepatic stellate cells via blocking SMAD and activating the PPARγ signaling pathway. Cells 8:1544–1560. https://doi.org/10.3390/cells8121544
doi: 10.3390/cells8121544
pmcid: 6952772